Resiquimod
As of the edition of 20 October 2026, Resiquimod is a small molecule: stopped in 2013; acts on TLR7 and TLR8.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2013
- Kind
- Small molecule
- Registered trials
- 17, 1 stopped early
- Disease areas
- Skin and connective tissue; Infections; Cancer; Immune system; Lungs and airways; Blood and lymph
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
2 company-target rows on route A because of this drug.
Companies on route A for this drug
In the product2 company-target rows are on route A because of Resiquimod.
See the 2 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 1 | 0 | 0 |
| Phase 1 | 2 | 2 | 0 | 0 |
| Phase 2 | 13 | 12 | 0 | 1 |
| All trials | 17 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Graceway Pharmaceuticals | Lead sponsor of trials | 2004 to now |
| Celldex Therapeutics | Lead sponsor of trials | 2009 to now |
| Spirig Pharma | Lead sponsor of trials | 2012 to now |
| Galderma | Lead sponsor of trials | 2017 to now |